Patients at the center – Does the JCA truly embrace the patients’ voice?
A key tenet of the JCA is to ensure faster access to innovative medicines and technologies for all patients across Europe. It seeks to achieve this by centralizing the health technology assessment of clinical evidence of new products and implementing rules to promote extensive stakeholder involvement1.
To explore the potential challenges and opportunities the JCA presents and understand to what extent the patient perspective will be incorporated, Cencora brought together a panel of experts for an in-depth webinar discussion. The session was moderated by Herbert Altmann, Head Commercialization and Access Solutions Europe, at PharmaLex, a Cencora company. Panelists included Antonella Cardone, CEO, Cancer Patients Europe (CPE), Matias Olsen, Senior Manager, Public Affairs and Policy, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), and Casper Paardekooper, Partner, Vintura, a Cencora company.
In the lead up to the webinar, we published an article on the patient perspective. The webinar takes that discussion further and into additional areas impacting patient involvement.
Will including the patient voice improve access to innovative medicines?
The implementation of the JCA will begin with oncology drugs and advanced therapy medicinal products (ATMPs) in January 2025, so it is a central topic for the European cancer community, Cardone noted. Although CPE welcomes the spirit of the Health Technology Assessment Regulation (HTAR), Cardone said it is not clear when and where patients will be involved in the process, under which criteria and how patients’ input will be taken into consideration.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.